Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines^{1,2} **Dose/Vial Color Recommendation Based on COVID-19 Vaccination History**

Not previously vaccinated: Three doses: 1st at week 0, 2nd at week 3-8, and 3rd ≥8 weeks after dose 2

1 previous Pfizer dose⁴: One dose 3-8 weeks after 1st dose and one dose ≥8 weeks after dose 2

Not previously vaccinated or Previously vaccinated⁴: Two doses given ≥4 months apart

Not previously vaccinated: Two doses: 1st at week 0 and 2nd 4-8 weeks after 1st dose

Not previously vaccinated or Previously vaccinated⁴: Two doses given ≥4 months apart

Not previously vaccinated: Three doses: 2 doses given 8 weeks apart⁵, followed by 1 additional dose ≥ 4 months

≥2 previous Pfizer doses⁴: One dose ≥8 weeks after last dose

1 previous Moderna dose⁴: One dose 4-8 weeks after last dose ≥2 previous Moderna doses⁴: One dose ≥8 weeks after last dose

Not previously vaccinated or Previously vaccinated4: One dose

Not previously vaccinated or Previously vaccinated⁴: One dose

Not previously vaccinated: Two doses 8 weeks apart⁵

Previously vaccinated4: One dose

5-11 years	10 mcg/0.3 mL; light blue cap and label	Not previously vaccinated or Previously vaccinated ⁴ : One dose
>12-64 vears	30 mcg/0 3 ml·gray can and lahel	Not previously vaccinated or Previously vaccinated4. One dose

≥65 years

Pfizer/BioNTech Vaccine (Comirnaty) – mRNA vaccine

3 mcg/0.3 mL; yellow cap and label

30 mcg/0.3 mL; gray cap and label

Moderna Vaccine (Spikevax) – mRNA vaccine 6 months-4 years³

Age

6 months-4 years³

5-11 years

≥65 years

≥65 years

≥12-64 years

25 mcg/0.25 mL; dark blue cap/green label

25 mcg/0.25 mL; dark blue cap/green label 50 mcg/0.5 mL; blue cap and label

50 mcg/0.5 mL; blue cap and label Novavax Vaccine – adjuvanted protein subunit vaccine

5 mcg (plus 50 mcg adjuvant)/0.5 mL; blue cap/label ≥12-64 years

The Johnson & Johnson (Janssen) vaccine is no longer available in the US.

after the last dose of updated 2023-2024 vaccine **Previously vaccinated**⁴: *Two* doses given ≥4 months apart 1. The updated 2023-2024 formula vaccines include a monovalent component that corresponds to the Omicron variant XBB.1.5. Previous bivalent Moderna and Pfizer/BioNTech and monovalent Novavax vaccines are no longer authorized for use in the US.

5 mcg (plus 50 mcg adjuvant)/0.5 mL; blue cap/label

For immunocompetent persons. Persons with moderate or severe immunocompromise may receive additional doses of the 2023-2024 COVID-19 formula vaccines based on the clinical judgement of a healthcare provider and personal preference and circumstances; additional doses should be given ≥2 months after the last 2023-2024 COVID-19 vaccine dose.

- Those vaccinated before September 12, 2023 with an age-appropriate previous version of the vaccine (not the updated 2023-2024 updated monovalent vaccine). Includes children who would turn 5 years old during the vaccination series. All doses should be from the same manufacturer.
- According to the CDC, an 8-week interval between doses might be optimal for some patients, especially adolescent and young adult males, to reduce the risk of myocarditis and pericarditis.
- The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying, or any other distribution of this material is strictly prohibited. Updated 3/10/2024